---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029447"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-06-22T23:59:59+00:00"
generated_at: "2026-06-13T19:13:08.233674+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Acrivon Therapeutics stockholders elect two Class I directors and ratify auditor

## Summary
- Michael Tomsicek elected Class I director with 17,527,002 votes for and 226,168 withheld.
- Charles Baum elected Class I director with 17,660,794 votes for and 91,113 withheld.
- Ratification of PricewaterhouseCoopers as auditor for FY2023: 17,879,658 for, 725 against.
- Quorum of 17,880,383 shares (81.55% of outstanding) present at the 2023 annual meeting.

## SEC filing metadata
- accession: 0000950170-23-029447
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-06-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017023029447/0000950170-23-029447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017023029447/acrv-20230622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029447
- JSON: https://secwatch.observer/filing/0000950170-23-029447.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029447.txt

## Key facts
- Shareholder Votes
  Acrivon Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-22 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following vote: For Against Abstain Broker Non-Votes 17,879,658 725 0 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000095017023029447/0000950170-23-029447-index.htm
- Shareholder Votes
  Acrivon Therapeutics, Inc. shareholders approved Election of Class I Director at the 2023-06-22 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal One: Election of Michael Tomsicek, M.B.A. as a Class I Director Michael Tomsicek was elected to serve as a Class I director to hold office until the Company’s 2026 Annual Meeting of Stockholders and until the election and qualification of his successor. Votes were cast as follows: For Withheld Broker Non-Votes Michael Tomsicek, M.B.A. 17,527,002 226,168 127,213
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000095017023029447/0000950170-23-029447-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.